Most Clicked StoriesMore >


Recommendations for beta-blockers after myocardial infaction: Should guidelines be reassessed?

AJMPlus | Oct 16, 2014

In contemporary practice of treatment of myocardial infarction, β-blockers have no mortality benefit but reduce recurrent myocardial infarction and angina (short-term) at the expense of increase in heart failure, cardiogenic shock and drug discontinuation. The guidelines should reconsider the strength of recommendations for β-blockers post-myocardial infarction. American Journal of Medicine, The (09/2014)


Exercise: An underfilled prescription

AJMPlus | Oct 09, 2014

Depression, diet and cardiovascular disease

AJMPlus | Oct 02, 2014

Statin use and risk of psychological disorders

AJMPlus | Oct 09, 2014

New onset atrial fibrillation predicts heart failure progression

AJMPlus | Oct 23, 2014

Accurate advanced screening for trisomies 21, 18 and 13

AJMPlus | Oct 09, 2014

The fractal nature of blood glucose fluctuations

AJMPlus | Oct 16, 2014

Incidence of drug-associated acute kidney injury

AJMPlus | Oct 09, 2014

Significance of positive family history for coronary heart disease

AJMPlus | Oct 16, 2014

Should diabetes screening be based on an age threshold?

AJMPlus | Oct 02, 2014


Find AJMPlus Issues by Date:





Sign up for AJMPlus



Designed specifically for healthcare professionals in clinical settings, AJM Plus is a FREE, weekly e-mail newsletter. By providing the latest, need-to-know medical headlines and news that affect healthcare professionals and patients, AJM Plus saves you time and keeps you smart. Sign up to receive your complimentary subscription today. Learn more